Corcept Therapeutics Faces FDA Setback as Relacorilant Approval Delayed by Complete Response Letter

Corcept Therapeutics Faces Regulatory Setback as FDA Issues Complete Response Letter for Relacorilant

Corcept Therapeutics Incorporated finds itself in troubled waters following a significant regulatory setback regarding its proposed treatment for hypercortisolism, relacorilant. On December 31, 2025, the U.S. Food and Drug Administration (FDA) issues a Complete Response Letter (CRL), which indicates that the agency requires further evidence to assess the drug's effectiveness before it can move forward with approval. This announcement comes despite Corcept's earlier assertions that relacorilant would generate annual revenues as high as $5 billion and that its new drug application was on track for a favorable review by the end of the year. The FDA's demand for additional proof of benefit-risk ratios starkly contrasts the company's optimistic projections, raising alarms about the potential overstating of relacorilant's clinical efficacy.

The FDA's CRL highlights that while Corcept's pivotal GRACE trial met its primary endpoint, and there was supportive evidence from the GRADIENT trial, further investigations are necessary to fully evaluate the treatment's benefit-risk profile. This unexpected blow sends shockwaves through the market, resulting in a staggering 50% drop in Corcept's share price and a loss of over $3.6 billion in market capitalization in just one day. Investors had placed significant faith in Corcept's assurances regarding the drug's potential, making this outcome particularly jarring. The disconnect between the company's previous messages and the FDA's current stance raises critical questions about the validity and reliability of Corcept's claims.

As a result of this situation, law firms such as Hagens Berman and the Schall Law Firm have launched investigations into potential securities law violations by Corcept. They aim to determine if the company misled investors regarding relacorilant's efficacy and commercial prospects. Reed Kathrein of Hagens Berman underscores the importance of assessing whether Corcept provided misleading information, encouraging shareholders who suffered losses to come forward. This scrutiny not only impacts Corcept's reputation but also highlights the regulatory challenges that biopharmaceutical companies face as they navigate the complex landscape of clinical trials and drug approvals.

In the wake of the CRL, Corcept Therapeutics may need to reevaluate its clinical strategy and communications with stakeholders. The necessity for additional evidence means that the company could face delays in bringing relacorilant to market, thereby affecting its financial forecasts and overall growth trajectory. As investigations unfold, the implications for both the firm's market position and investor confidence will be closely monitored.

With the FDA's expectations for drug approvals becoming increasingly stringent, Corcept's experience serves as a cautionary tale for other companies in the biopharmaceutical industry. The fallout from this incident may prompt broader discussions about transparency and accountability in drug development, as both the regulatory landscape and investor trust become critical factors in the success of therapeutic innovations.